NCT06660524View on ClinicalTrials.gov

Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

PHASE4RecruitingINTERVENTIONAL
Enrollment

196

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Degenerative Heart Valve DiseaseHeart Valve CalcificationChronic Kidney Disease(CKD)Calcium-Phosphorus Metabolism Disorders
Interventions
DRUG

Sevelamer

Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.

DRUG

Calcium carbonate

Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.

Trial Locations (1)

100037

RECRUITING

Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV